Eurizon Capital SGR S.p.A. Invests $23.03 Million in Biogen Inc. $BIIB

Eurizon Capital SGR S.p.A. bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 130,813 shares of the biotechnology company’s stock, valued at approximately $23,025,000. Eurizon Capital SGR S.p.A. owned 0.09% of Biogen at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rothschild Investment LLC grew its position in Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares during the period. Advisory Services Network LLC grew its position in Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares during the period. Davis Investment Partners LLC grew its position in Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after buying an additional 71 shares during the period. Optas LLC grew its position in Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after buying an additional 73 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in Biogen by 8.1% during the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after buying an additional 89 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

NASDAQ:BIIB opened at $196.00 on Friday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The company has a market cap of $28.94 billion, a P/E ratio of 21.03, a P/E/G ratio of 1.73 and a beta of 0.19. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97. The firm’s 50 day moving average is $186.66 and its two-hundred day moving average is $182.21.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the firm posted $3.02 earnings per share. Biogen’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Analysts expect that Biogen Inc. will post 14.18 EPS for the current year.

Analyst Ratings Changes

Several brokerages have weighed in on BIIB. TD Cowen upped their target price on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Argus upgraded shares of Biogen to a “hold” rating in a research report on Thursday, April 9th. Truist Financial lowered their target price on shares of Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research report on Monday, April 13th. Barclays began coverage on shares of Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target on the stock. Finally, Evercore began coverage on shares of Biogen in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $215.81.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.